A post-hoc safety analysis of the phase 3 OptiTROP-Breast01 trial found that sacituzumab tirumotecan's key adverse events ...
A new narrative review argues that GLP-1 receptor agonists should be repositioned as foundational cardio-renal-metabolic protectors, with trial evidence extending well beyond glucose lowering.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results